UroGen Pharma Ltd. (URGN) Free cash flow 2016–2025
UroGen Pharma Ltd. (URGN) annual free cash flow history — operating cash flow minus capital expenditures, per SEC filings.
-$162.7MFY2025 · since FY2016: $3.5M → -$162.7M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$162.7M | -67.7% |
| FY2024 | -$97.1M | -26.8% |
| FY2023 | -$76.6M | +12.8% |
| FY2022 | -$87.8M | -2.5% |
| FY2021 | -$85.6M | +20.0% |
| FY2020 | -$107.1M | -50.1% |
| FY2019 | -$71.3M | -88.3% |
| FY2018 | -$37.9M | -285.1% |
| FY2017 | -$9.8M | -381.6% |
| FY2016 | $3.5M | — |
Free cash flow = reported operating cash flow − reported capital expenditures for the same fiscal year.
Source: SEC XBRL filings · For reference only · Not investment advice